Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nozomu Kawata is active.

Publication


Featured researches published by Nozomu Kawata.


BJUI | 2005

Clinical staging of prostate cancer : a computer-simulated study of transperineal prostate biopsy

E. David Crawford; Shandra Wilson; Kathleen C. Torkko; Daisaku Hirano; J. Scott Stewart; Craig Brammell; R. Storey Wilson; Nozomu Kawata; Holly T. Sullivan; M. Scott Lucia; Priya N. Werahera

To identify the precise location of prostate cancer within the gland and thus possibly permit more aggressive therapy of the lesion, while potentially sparing the noncancerous gland from ablative therapy.


International Journal of Urology | 2003

Histopathological analysis of angiogenic factors in renal cell carcinoma

Hiroki Yagasaki; Nozomu Kawata; Yukie Takimoto; Norimichi Nemoto

Aim: The present study was carried out to clarify whether a histopathological analysis of vascular endothelial growth factor (VEGF), transforming growth factor‐β1 (TGF‐β1) and matrix metalloproteinase 2 (MMP‐2) can help predict the outcome of renal cell carcinoma (RCC). We examined the expression of VEGF, TGF‐β1 and MMP‐2 in a large series of RCC with a long follow‐up, based on histopathological factors and survival.


Urologia Internationalis | 2012

Intravesical Recurrence after Surgical Management of Urothelial Carcinoma of the Upper Urinary Tract

Daisaku Hirano; Yasuhiro Okada; Yusuke Nagane; K. Satoh; Junichi Mochida; Yataroh Yamanaka; Hitoshi Hirakata; Kenya Yamaguchi; Nozomu Kawata; Satoru Takahashi; Akihiro Henmi

Objectives: To elucidate clinicopathological risk factors for intravesical recurrence (IVR) in patients undergoing nephroureterectomy for upper urinary tract urothelial carcinoma (UUT-UC). Methods: We identified a study population of 151 consecutive patients without previous or concurrent bladder cancer who underwent nephroureterectomy for UUT-UC. IVR was assessed in relation to tumor location, size, and multifocality, operation modality and time, stage, grade, lymphovascular invasion, regional lymph node metastasis, preoperative urinary cytology, and perioperative chemotherapy. The median follow-up time was 24 months. Results: Of 151 patients, 51 (34%) developed IVR after nephroureterectomy, and 50 (98%) of the patients presented with IVR within 2 years. Tumor multifocality and site (located in ureter) were determined as risk factors for IVR by univariate analysis. In a multivariate analysis, only tumor multifocality (relative risk: 4.024, p = 0.001) was an independent predictor of IVR. Ten-year cancer-specific survival rates for the patients with and without IVR were 68 and 52%, respectively (p = 0.06). Conclusions: Tumor multifocality is a significant risk factor in developing IVR after surgery for UUT-UC. These results indicate that despite most IVR occurring within 2 years of treatment, it is necessary to follow such patients more closely using cystoscopy. However, IVR is unlikely to indicate a poorer prognosis.


International Journal of Urology | 2008

How do symptoms have an impact on the prognosis of renal cell carcinoma

Nozomu Kawata; Yusuke Nagane; Kenya Yamaguchi; Taketo Ichinose; Hitoshi Hirakata; Satoru Takahashi

Aim:  Symptomatic renal cell carcinoma (RCC) is well known to have a characteristic behavior. We therefore evaluated the impact of systemic symptoms on the prognosis of RCC.


International Journal of Urology | 1997

ELECTRON MICROSCOPIC STUDY OF THE PENILE PLAQUES AND ADJACENT CORPORA CAVERNOSA IN PEYRONIE'S DISEASE

Daisaku Hirano; Yukie Takimoto; Tadao Yamamoto; Hitoshi Hirakata; Nozomu Kawata

Background We conducted ultrastructural studies to clarify the fine structure of penile plaques and adjacent corpora cavernosa, and the causative basis for the process, in Peyronies disease.


International Journal of Urology | 2000

Cytoreductive surgery with liver-involved renal cell carcinoma

Nozomu Kawata; Hitoshi Hirakata; Humikazu Yuge; Masahito Kodama; Shuji Sugimoto; Hiroki Yagasaki; Junichi Mochida; Kei Fujimura; Yukie Takimoto

The purpose of this study was to demonstrate the benefits of cytoreductive surgery for renal cell carcinomas that also involve the liver. Between 1994 and 1997, four patients with renal cell carcinoma with liver involvement were surgically treated with nephrectomy and hepatectomy. Two of them underwent a simultaneous hepatectomy and nephrectomy (group 1), and the remaining two patients underwent a hepatectomy after a nephrectomy and had a diagnosis of postoperative recurrence (group 2). Two patients, one from each group, died of multiple bone metastasis and lung metastasis 30 months and 12 months after the hepatectomy; the second patient from group 1 died 40 months after the first operation due to gastrointestinal hemorrhaging. The second patient from group 2 displayed no evidence of recurrence 18 months after the second surgical procedure. The survival rates for these patients were 66% and 33% at 1 and 3 years, respectively. Autopsy studies revealed that one patient from group 2 had a local recurrence in the liver while the other two patients from group 1 did not. Our results suggested that a progressive approach may therefore be useful for patients demonstrating renal cell carcinoma where there is liver involvement.


The Japanese Journal of Urology | 1999

[The effect of 5-HT 2 antagonist for urinary frequency symptom on diabetes mellitus patients].

Yukie Takimoto; Masahito Kodama; Shuuji Sugimoto; Takamasa Hamada; Takuro Fuse; Nozomu Kawata; Hitoshi Hirakata; Hiromi Hosokawa

17 cases of patients with diabetes mellitus who had urinary frequency symptom for which anti-cholinergic agents proved ineffective were given Sarpogrelate Hydrochloride (Anplag), a selective 5-HT 2 receptor antagonist. Efficacy was judged using IPSS and QOL scores after 2 weeks medications, these showed that all cases had improved their urinary frequency during the days as well as the night. This was especially true for the QOL score. One time urinary volume markedly increased, but there was no statistical significance after medication in maximum flow rate and residual urine. At the same time, a separate group of 14 mainly BPH cases did not improve entirely. It is believed that reaction in the detrusor muscle with hyperreflexia of diabetes mellitus patients can reach 5-HT, and its reaction is believed to reach via the 5-HT 2 receptor. This paper is a first clinical report of making use of 5-HT 2 antagonist as hyperactive detrusor on diabetes mellitus patients.


International Journal of Urology | 2001

Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: The influence of neoadjuvant treatment

Nozomu Kawata; Hiroki Yagasaki; Humikazu Yuge; Yuji Nakanoya; Kei Fujimura; Shuji Sugimoto; Hitoshi Hirakata; Yukie Takimoto

This study was conducted in order to clarify whether histopathologic analysis of factor thymidine phosphorylase (TP) and Factor VIII could be a useful predictor of postoperative recurrence in localized renal cell carcinoma. Therefore, the relationship between tumor infiltrated lymphocytes (TIL) and both TP and Factor VIII was studied.


Scandinavian Journal of Urology and Nephrology | 2007

Implications of circulating chromogranin A in prostate cancer

Daisaku Hirano; Sadatsugu Minei; Shuji Sugimoto; Kenya Yamaguchi; Tetsuo Yoshikawa; Takahiko Hachiya; Nozomu Kawata; Toshio Yoshida; Satoru Takahashi

Objective. To evaluate whether measurement of circulating chromogranin A (CgA) levels provides clinicopathological and prognostic information in prostate cancer. Material and methods. Plasma CgA levels were measured in 57 patients with histologically confirmed prostate cancer (stage B or less, n=22; stage C, n=10; stage D1, n=2; hormone-naive D2, n=12; hormone-refractory D2, n=11) and in 22 with undetected prostate cancer using an enzyme-linked immunoabsorbent assay. Results. Median plasma CgA levels were significantly higher in patients with prostate cancer than in those with undetected cancer (p=0.0271). Higher stage (p<0.0001) and higher grade (p=0.0412) tumours were also significantly associated with higher plasma CgA levels. Above-normal CgA levels were also detected in 4/27 patients (15%) who underwent radical prostatectomy. Postoperative clinical failure was not reported in the prostatectomy patients; however, prostate-specific antigen (PSA) failure was reported in 44% of patients after a median follow-up period of 20.3 months. Multivariate analysis revealed that the pathological stage of the tumour was the only independent predictive variable for postoperative PSA failure (p=0.0494). Preoperative plasma CgA levels had no impact on postoperative PSA failure in the subgroup (prostatectomy patients). Elevated plasma CgA levels were associated with a poor survival prognosis in patients with stage D2 prostate cancer after a median follow-up period of 22.5 months (p=0.0416). Conclusions. It was demonstrated in this study that plasma CgA levels in prostate cancer increase with the severity of the disease, especially for progressive hormone-refractory prostate cancer (HRPC), after hormone therapy. Although this cross-sectional study involved only a small number of patients, we believe that plasma CgA levels may effectively predict HRPC status and prognosis in metastatic cases.


World Journal of Surgical Oncology | 2015

Solitary pulmonary metastasis from prostate cancer with neuroendocrine differentiation: a case report and review of relevant cases from the literature

Toshiya Maebayashi; Katsumi Abe; Takuya Aizawa; Masakuni Sakaguchi; Naoya Ishibash; Shoko Fukushima; Taku Honma; Yoshiaki Kusumi; Tsuyoshi Matsui; Nozomu Kawata

BackgroundSolitary lung metastasis from prostate cancer is rare. There are few reports of such cases with neuroendocrine differentiation.Case presentationA 50-year-old man presented to our hospital with a chief complaint of dysuria. Histological examination revealed prostate cancer, which was classified as cT4 N0 M0, stage IV adenocarcinoma. Since the patient was at high risk, endocrine and radiation therapies were started. One year after starting radiation therapy, the patient developed bloody sputum. Chest radiography revealed a nodular shadow in his left lung (S5). Although 18-fluoro-2-deoxyglucose positron emission tomography revealed abnormal accumulation in the lesion, the cytological diagnosis was class IIIa, which did not yield a definitive diagnosis. Given that prostate specific antigen (PSA) was not elevated, a primary lung tumor was suspected, and thoracoscopic segmental resection of the lung was performed with lymph node dissection. The final pathological diagnosis was solitary lung metastasis from prostate cancer with neuroendocrine differentiation and mediastinal lymph node metastasis. The specimen showed a mixed pattern of conventional prostatic and neuroendocrine carcinomas.ConclusionWe herein report a case with neuroendocrine differentiation (NED), along with a review of the relevant literature, including histopathological findings. According to previous case reports, some patients with solitary lung metastasis from prostate cancer achieved relatively good long-term survival. We consider establishing the correct diagnosis and implementing an appropriate treatment plan to be essential in prostate cancer patients with oligometastases that have the potential to be neuroendocrine (NE) tumors.

Collaboration


Dive into the Nozomu Kawata's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge